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Abstract: This open-label, phase 3b study (ClinicalTrials.gov Identifier: NCT00983073) 
evaluated the effectiveness, and tolerability of tapentadol for severe, chronic osteoarthritis 
knee pain that was inadequately managed with World Health Organization (WHO) Step I or II 
analgesics or co-analgesics, or that was not treated with regular analgesics. Prior to starting study 
treatment, patients discontinued any WHO Step II analgesics, while Step I analgesics and/or 
co-analgesics were continued at the same dose. Patients received tapentadol prolonged release 
(50–250 mg bid) during a 5-week titration period and a 7-week maintenance period. Doses of 
tapentadol immediate release 50 mg (#twice/day; $4 hours apart) were permitted throughout 
the study (total daily dose of tapentadol prolonged and immediate release, #250 mg bid). The 
primary endpoint was the change in pain intensity on an 11-point numerical rating scale-3 
(NRS-3; recalled average pain intensity [11-point NRS] during the last 3 days) from baseline 
to Week 6, using the last observation carried forward (LOCF) to impute missing pain intensity 
scores. The mean (standard deviation) change from baseline to Week 6 (LOCF) in pain intensity 
was −3.4 (2.10; P , 0.0001) for all patients evaluated for effectiveness (n = 195). Significant 
decreases in pain intensity were also observed at Weeks 6, 8, and 12 (all P , 0.0001) using 
observed-case analysis. Corresponding significant improvements from baseline to Weeks 6 and 
12 were observed in the Western Ontario and McMaster Universities osteoarthritis index, the 
EuroQol-5 Dimension health status questionnaire, the Short Form-36 health survey, and the 
Hospital Anxiety and Depression Scale (all P # 0.0103). Treatment-emergent adverse events 
were in line with those observed in previous studies of tapentadol prolonged release. Overall, 
the results of this study indicate that tapentadol treatment results in significant improvements in 
pain intensity, health-related quality of life, and function in patients with inadequately managed, 
severe, chronic osteoarthritis knee pain.
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Introduction
Osteoarthritis is the most common form of arthritis1,2; the prevalence of osteoar-
thritis ranges from 10.8% to 14.7% in the general adult population in developed 
countries and increases with increasing age.2 In a study of approximately 4 million 
patients who visited health care professionals or hospitals in British Columbia in 
2001, the estimated prevalence of osteoarthritis increased from 6.9% for patients 
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40 to 44 years of age to 26.4% for patients 60 to 64 years 
of age and 49.0% for patients 80 to 84 years of age.3 
Symptomatic osteoarthritis most commonly affects the 
knees, hips, hands, or feet.4 Osteoarthritis pain can have a 
significant negative impact on health-related quality of life 
and may be associated with an increased risk of anxiety 
or depression.5,6 In addition, osteoarthritis-related knee 
and hip pain are the primary causes of reduced mobility 
among the elderly.7
Opioid analgesics have been shown to relieve osteoarthritis 
pain8–10 and to improve health-related quality of life and 
physical function.11 Opioid treatment may not be effective 
for all patients with osteoarthritis pain because of variations 
in patient response to pure µ-opioid agonist treatment,12 
which may be caused by multiple factors, including different 
degrees of central sensitization.13,14 In addition, there is 
evidence that descending inhibitory pain pathways are 
disrupted in chronic musculoskeletal pain conditions, and 
pharmacotherapies that target descending pain pathways 
(eg, those that block serotonin or norepinephrine reuptake) 
may be more appropriate for managing chronic pain than 
pure µ-opioid receptor agonists.13,15,16 Drugs possessing both 
norepinephrine reuptake inhibition and serotonin reuptake 
inhibition abilities may have a less clear analgesic profile 
because the serotonergic component of their mechanism of 
action can enhance descending pain inhibition (resulting in 
an analgesic effect) or facilitate pain signaling (resulting 
in a pro-algesic effect).17,18 Variations in patient response 
to opioid analgesia and the contribution of dysfunction of 
descending inhibitory pain pathways may leave some patients 
treated with pure µ-opioid receptor agonists or co-analgesics 
with undermanaged osteoarthritis pain and corresponding 
poor health status and quality of life.12,13 In addition, opioid 
analgesics are often associated with side effects, particularly 
gastrointestinal side effects, that may limit patients’ long-
term compliance with treatment.19–21
Tapentadol is a centrally acting analgesic that acts 
through µ-opioid receptor agonism and noradrenaline 
reuptake inhibition.22,23 The efficacy and safety of tapentadol 
prolonged release (100–250 mg bid) for the management 
of moderate to severe, chronic osteoarthritis pain has 
been assessed.24–26 The current open-label phase 3b study 
(ClinicalTrials.gov Identifier: NCT00983073) evaluated the 
effectiveness and tolerability of tapentadol in patients with 
severe, chronic osteoarthritis knee pain that was inadequately 
managed with World Health Organization (WHO) Step I 
or II analgesics or co-analgesics or that was not treated with 
regular analgesics.
Patients and methods
Patient population
Patients were selected for this study based on the following 
inclusion criteria:
•	 At least 40 years of age
•	 A diagnosis of osteoarthritis of the knee based on the 
American College of Rheumatology classification criteria 
(knee pain and radiographic osteophytes or at least 
40 years of age with knee pain, morning stiffness of at least 
30 minutes duration, and crepitus on motion); patients with 
osteoarthritis at joints other than the reference knee joint 
were allowed to participate in the study if the reference 
joint was the main source of pain and disability
•	 Pain at the reference joint for a minimum of 3 months 
prior to screening
•	 WHO Step I or II analgesic treatment for osteoarthritis-
  related knee pain for a minimum of 2 weeks before screen-
ing (for patients taking regular daily pretreatment)
•	 Pain requiring a strong (WHO Step III) analgesic that 
could not be adequately managed with an increase in 
the dose of WHO Step I analgesics (as monotherapy or 
combination therapy) or continuation with or an increase 
in the dose of WHO Step II analgesics (based on the 
investigator’s assessment)
•	 Average pain intensity score at screening of at least 5 on 
an 11-point numerical rating scale-3 (NRS-3; recalled 
average pain intensity [11-point NRS] during the 3 days 
before a study visit; 0 = “no pain” to 10 = “pain as bad as 
you can imagine”) for patients taking regular pretreatment 
with WHO Step I or II analgesics
•	 Average pain intensity score at screening of at least 6 
(11-point NRS-3) for patients taking no regular daily 
pretreatment
•	 Ratings of satisfaction with prior analgesic treatment 
(either WHO Step I or II analgesics or no regular 
pretreatment) of not better than “fair” on a 5-point verbal 
rating scale (VRS; 0 = “poor”, 1 = “fair”, 2 = “good”, 
3 = “very good”, 4 = “excellent”)
Patients were excluded from the study based on the 
  following criteria:
•	 Pregnancy or lactation
•	 Known or suspected inability to comply with the protocol 
and use of study medication
•	 Participation in another study concurrently or within 
4 weeks prior to screening
•	 Any painful procedure (eg, major surgery or surgery at 
the reference joint) required during the study that could 
impact effectiveness and safety assessments
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•	 Clinically significant disease, laboratory findings, 
active systemic or local infection, conditions other than 
osteoarthritis at the reference joint, significant skin 
  conditions (eg, abscess), widespread pain syndromes 
(eg, fibromyalgia), or other concomitant painful condi-
tions that could interfere with pain intensity, quality of 
life, function, or safety assessments
•	 Osteoarthritis in a flare state or a history and clinical signs 
of crystal-induced (eg, gout or pseudogout), metabolic, 
infectious, or autoimmune disease at the reference joint
•	 Concomitant autoimmune inflammatory conditions
•	 A history of human immunodeficiency virus infection
•	 A history of alcohol or drug abuse
•	 A history of, or laboratory values reflecting, severe renal 
impairment or a history of moderate or severe hepatic 
impairment
•	 A history of active hepatitis B or C within the 3 months 
prior to screening
•	 A history of brain neoplasm, transient ischemic attack, 
stroke, or mild or moderate traumatic brain injury within 
the year prior to screening or residual sequelae   indicative 
of transient changes in consciousness or a history of 
severe traumatic brain injury within 15 years prior to 
screening
•	 Contraindications to tapentadol (eg, known or suspected 
paralytic ileus or acute or severe bronchial asthma or 
hypercapnia) or a history of allergy or hypersensitivity 
to tapentadol or its excipients
The following drugs were prohibited during the study 
and within the specified timeframes prior to screening: 
monoamine oxidase inhibitors within 14 days of screening, 
unstably dosed selective serotonin reuptake inhibitors within 
30 days of screening, WHO Step III analgesics within 30 days 
of screening, and intra-articular injections of hyaluronic acid 
in the reference joint within 3 months of screening. Patients 
were permitted to take serotonin reuptake inhibitors if their 
doses remained stable throughout the study.
Study design
This phase 3b study had an open-label, multicenter design 
with a 12-week treatment period with tapentadol, including 
a 5-week titration period and a 7-week maintenance period. 
The titration period was immediately preceded by a 1-week 
observation period under the previous analgesic treatment 
regimen (Week −1) that started with the screening visit and 
ended with the baseline visit; during the titration period, all 
analgesics, co-analgesics, and drugs for the treatment of 
opioid-induced side effects were recorded by the patients 
in a daily diary. Patients continued taking their pre-study 
regimens of all WHO Step I analgesics, co-analgesics, and 
drugs for the treatment of opioid-induced side effects with no 
further dose adjustments during the titration period and the 
remainder of the study (unless they were participating in a 
tapering substudy as described below). Doses of non-  steroidal 
anti-inflammatory drugs (NSAIDs) could be increased 
for documented inflammatory flares of osteoarthritis and 
laxatives could be discontinued if laxative-induced diarrhea 
occurred after patients switched to tapentadol prolonged 
release. Patients taking WHO Step II analgesics discontinued 
these analgesics at the end of the observation period (on the 
evening of the day of the baseline visit).
On the morning after the baseline visit, eligible patients 
initiated study treatment with tapentadol prolonged release 
50 mg bid. Three days after the start of study medica-
tion, an initial titration was permitted if necessary. Doses 
of tapentadol prolonged release were then titrated each 
week as needed (within the therapeutic dose range of 
50–250 mg bid) until patients achieved at least a 1-point 
decrease in their pain intensity score (11-point NRS-3) 
from baseline, which was defined as a clinically relevant 
improvement in pain relief and was the minimum target 
of titration. Titration was continued until at least the 
minimum target of titration was reached or the patient was 
taking tapentadol prolonged release 250 mg bid. Doses of 
tapentadol prolonged release could then be titrated (up to 
a maximum of 250 mg bid) until patient satisfaction with 
treatment (5-point VRS) was rated as “good” or better and 
pain intensity scores (11-point NRS-3) were reduced by 
2 or more points from baseline or were no more than 4. 
If a dose increase did not lead to further improvement in 
patient satisfaction (5-point VRS) of at least 1 point or a 
decrease in the pain intensity score (11-point NRS-3) of 
at least 1 point at the next study visit, the dose could be 
decreased to the previous level.
Patients were permitted to take tapentadol immediate 
release 50 mg (#twice daily; $4 hours apart) throughout 
the 12-week treatment period; the maximum total daily dose 
of tapentadol (prolonged release and immediate release) was 
not allowed to exceed 500 mg per day. Tapentadol immediate 
release was allowed for acute pain episodes due to index pain 
that had no clear cause, that were associated with increased 
activity or movement (incidental pain), or that resulted from 
end-of-dose failure (indicating that the dose of tapentadol 
prolonged release should be increased); tapentadol immedi-
ate release was also permitted for the relief of withdrawal 
symptoms (eg, hyperalgesia) that might occur during the first 
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days of the titration period following discontinuation of prior 
WHO Step II opioids.
During the 7-week maintenance period, patients continued 
taking their optimal doses of tapentadol prolonged release 
and tapentadol immediate release, which were determined 
during the titration period. All other WHO Step I analgesics, 
co-analgesics, and medications used to control side effects 
associated with previous WHO Step II analgesic treatment 
were continued at the same stable doses unless patients 
elected to participate in a tapering substudy (Substudy A), in 
which WHO Step I analgesics or co-analgesics were tapered 
during the 3-week period from Week 9 to Week 11.
Effectiveness, function, quality- 
of-life, and tolerability evaluations
Patients rated their recalled average pain intensity using 
the 11-point NRS-3 at screening, at baseline, and at all 
study visits; the pain intensity ratings at baseline and all 
subsequent study visits referred to the index joint, which 
was the knee with a higher pain intensity score at screening. 
The primary endpoint was the change from baseline to 
Week 6 (the first week of the maintenance period) in average 
pain intensity on the 11-point NRS-3; the last observation 
carried forward (LOCF) was used to impute missing pain 
intensity assessments in the event of early discontinuation. 
Additional assessments included responder rates 1 and 2; the 
change from baseline to Weeks 6, 8, and 12 in pain intensity 
(11-point NRS-3) using observed-case analysis; the patient 
global impression of change (PGIC);27,28 the clinician global 
impression of change (CGIC);29 patient satisfaction with 
treatment; the Western Ontario and McMaster Universities 
(WOMAC) osteoarthritis index;30 the EuroQol-5 Dimension 
(EQ-5D) health status questionnaire;31 the Short Form-36 
(SF-36) health survey;32 and the Hospital Anxiety and 
Depression Scale (HADS).33 Total daily doses of tapentadol 
prolonged release and tapentadol immediate release were 
also recorded throughout the study.
Responder rate 1 was defined as the percentage of patients 
with a decrease of at least 1 point in average pain intensity 
from baseline on the 11-point NRS-3. Responder rate 2 was 
defined as the percentage of patients with a decrease of at least 
1 point in average pain intensity from baseline on the 11-point 
NRS-3 and an improvement of at least 1 category in patient-
rated satisfaction with treatment on the 5-point VRS.
The PGIC,27,28 which was completed at each study visit, 
was used to evaluate patients’ impressions of change in their 
overall condition with trial treatment using a scale from 1 
to 7 (1 = “very much improved” to 7 = “very much worse”). 
The CGIC29 was also completed at each study visit and was 
used to evaluate the investigator’s impression of the change 
in a patient’s condition from baseline using the same 7-point 
scale. Patients rated their satisfaction with their previous 
treatment (WHO Step II analgesics, WHO Step I analgesics, 
co-analgesics, or no regular analgesic treatment) at screening 
and baseline using the 5-point VRS, and patients rated their 
satisfaction with study treatment (tapentadol prolonged 
release) at each study visit.
The WOMAC osteoarthritis index,30 EQ-5D health 
status questionnaire,31 and SF-36 health survey32 were used 
to evaluate health-related quality of life. The WOMAC 
osteoarthritis index,30 which was completed at screening 
and baseline and at each study visit, is a validated 24-item 
questionnaire that is used to evaluate pain, disability, and 
joint stiffness in patients with knee and hip osteoarthritis; 
each item was rated on a scale from 0 to 5, with lower 
scores indicating lower levels of symptoms. The EQ-5D 
health status questionnaire and the SF-36 health survey 
were both completed at screening and baseline, at Weeks 1 
and 5, and at all subsequent study visits. The EQ-5D health 
status questionnaire31 includes 5 dimensions of health-related 
quality of life (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression), each of which was 
scored using one of the following levels: “no problems”, 
“some problems”, or “extreme problems”. The SF-36 
health survey32 includes 8 dimensions that evaluate bodily 
pain, general health perceptions, vitality, mental health, and 
limitations in physical and social activities; all 8 dimensions 
were scored on a scale from 0 to 100, with higher scores 
indicating better health.
Patients completed the HADS at screening and baseline, 
at Weeks 1 and 5, and at all subsequent study visits. The 
HADS33 consists of 14 questions that evaluate anxiety and 
depression in medically compromised patients; each ques-
tion was scored from 0 to 3 and higher scores indicated more 
severe symptoms of anxiety and depression.
Adverse events (AEs) were recorded throughout the study. 
An AE was defined as any untoward medical occurrence 
(including any unfavorable and unintended signs, symptoms, 
or diseases) in a patient who was enrolled in the study and 
that occurred during the observation period (prior to receiving 
the study treatment) or during the active treatment period 
(after starting the study treatment); an AE was not necessarily 
related to study treatment. A non–treatment-emergent AE 
was defined as any AE that occurred or was present prior to 
the start of study treatment; all ongoing medical conditions 
without a stop date prior to enrollment were recorded as 
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non–treatment-emergent AEs during the observation period 
of this study. A treatment-emergent AE (TEAE) was any 
AE that newly occurred or worsened in intensity, frequency, 
or quality after the first intake of study medication. The 
relationship of TEAEs to tapentadol treatment and the 
association of AEs with previously or concomitantly received 
WHO Step I or II analgesics or co-analgesics were evaluated, 
as described in the Appendix. A serious AE was defined as 
any AE that resulted in death, was life-threatening, required 
in-patient hospitalization or prolongation of an existing 
hospitalization, resulted in persistent or significant disability 
or incapacity, resulted in a congenital anomaly or birth defect, 
or was considered medically important.
Statistical analyses
Based on a standard deviation (SD) in the mean pain intensity 
score (11-point NRS-3) of 3, it was estimated that a sample 
of 73 patients would be required to provide 80% power for 
detecting a difference between a clinically relevant mean pain 
intensity score of 4 and the null hypothesis mean pain inten-
sity score of 5 at Week 6 at α = 0.05. Given the rejection of 
the null hypothesis for the primary endpoint, responder rates 1 
and 2 were evaluated in a step-wise manner. It was estimated 
that a sample size of 177 patients would be required to provide 
85% power to detect a difference between a clinically relevant 
response rate 1 of 60% and the null hypothesis response rate 
of 50% at α = 0.05.
All patients who took at least 1 dose of study medication 
were included in the safety population, and all patients who 
took at least 1 dose of study medication and had 1 or more 
post-baseline pain intensity assessments were included 
in the main analysis population, which was used for all 
effectiveness, quality of life, and functionality analyses. Pain 
intensity (11-point NRS-3) was evaluated by prior opioid 
experience; opioid-experienced patients were those who 
had taken WHO Step II opioid analgesics prior to receiving 
study treatment and opioid-naïve patients were those who had 
not taken WHO Step II opioid analgesics prior to receiving 
study treatment. The primary endpoint (the change from 
baseline to Week 6 in pain intensity [11-point NRS-3] using 
the LOCF) was evaluated using a one-sample paired t test, as 
were the changes from baseline to Weeks 6, 8, and 12 using 
observed-case analysis.
For the WOMAC osteoarthritis index, the individual item 
scores for each of the 3 dimensions (pain [5 items], stiffness 
[2 items], and physical function [17 items]) were summed 
to produce subscale scores for each dimension; the possible 
score for the pain subscale ranged from 0 to 20, the possible 
score for the stiffness subscale ranged from 0 to 8, and 
the possible score for the physical function subscale ranged 
from 0 to 68.34 The 3 subscale scores were then summed 
to produce a WOMAC global score (possible score, 0–96). 
For the EQ-5D health status index, a health status index 
score from 0–1 (0 = “dead” to 1 = “full health”) was derived 
using weighted responses for each of the individual EQ-5D 
dimensions. Weighted combinations of the SF-36 subscale 
scores were used to calculate a physical component summary 
score and a mental component summary score, both of which 
have a possible range of scores from 0–100 (where higher 
scores indicate better health). For the HADS, 7 items were 
combined to yield an anxiety subscale score (possible score, 
0–21) and the remaining 7 items were combined to yield a 
depression subscale score (possible score, 0–21). For the 
HADS anxiety and depression subscale scores, a score of   
0–7 is considered to be in the normal range, while a score of 
8 or more is considered to be suggestive or indicative of the 
probable presence of anxiety or depression.35 A one-sample 
paired t test was used to analyze the changes from baseline 
to Week 6 and Week 12 in the 3 WOMAC subscale scores 
and the WOMAC global score, the changes from baseline 
to Week 6 and Week 12 in the EQ-5D health status index, 
the changes from baseline to Week 6 in the 8 SF-36 subscale 
scores and the 2 SF-36 summary scores, and the changes 
from baseline to Week 6 and Week 12 in the HADS anxiety 
and depression subscale scores.
Tapering of WHO Step I analgesics and co-analgesics 
during Weeks 9 through 12 in Substudy A could theoretically 
have resulted in pain peaks that could influence effectiveness, 
function, and quality-of-life results. For that reason, separate 
analyses were performed for effectiveness, function, and 
quality-of-life measures for a data set that excluded results 
from Weeks 9 through 12 for patients who participated in 
Substudy A and for another data set that included results from 
Weeks 9 through 12 for these patients. In addition, results 
of all effectiveness, function, and quality-of-life measures 
(excluding Weeks 9 through 12 for patients who participated 
in Substudy A) were evaluated using observed-case analysis 
and using the LOCF for imputing missing assessments. 
Separate analyses were performed for the subset of patients 
who participated in Substudy A (n = 21); tapering of WHO 
Step I analgesics and co-analgesics and the results of pain 
intensity and responder rate analyses will be briefly described 
for this subset of patients. The effectiveness, function, and 
quality-of-life analyses presented in this manuscript are for 
the data set that excluded results from Weeks 9 through 
12 for patients who participated in Substudy A and used 
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observed-case analysis unless otherwise specified. Additional 
effectiveness, function, and quality-of-life results for the 
population that included results from Weeks 9 through 12 
for patients who participated in Substudy A and using the 
LOCF for imputing missing assessments (excluding Weeks 
9 through 12 for patients who participated in Substudy A) 
are summarized in the Appendix.
Results
Patients and treatment exposure
Overall, 224 patients enrolled in the study; 200 patients 
received at least 1 dose of study medication and were 
included in the safety population, and 195 patients received 
at least 1 dose of study medication and had at least 1 post-
baseline pain intensity assessment and were included in the 
main analysis population. In the safety population (n = 200), 
the mean (SD) age was 67.4 (10.81) years, and patients 
ranged in age from 42 to 94 years. The mean (SD) body mass 
index in the safety population was 31.9 (5.92) kg/m2, and the 
majority of patients were female (67.5%) and white (98.0%). 
Details of the patients’ histories of osteoarthritis knee pain, 
including mean values for the duration of pain, time to first 
pain-related visit consultation, time off work per year due 
to pain, number of doctors visited, number of consultations 
(overall and unplanned), and number of analgesic regimens 
taken since the pain started, are summarized in Figure 1.
A total of 29.0% (58/200) of patients were taking WHO 
Step II analgesics during Week −1. The types of WHO 
Step II analgesics that patients were taking during Week −1 
are summarized in Table 1. Overall, 64.5% (129/200) of 
patients took WHO Step I analgesics and 17.0% (34/200) 
of patients took co-analgesics concomitantly during the 
study. The most frequently used concomitant WHO Step 
I analgesics (used by $2% of patients) were paracetamol 
(21.0% [42/200]), diclofenac (19.0% [38/200]), ibupro-
fen (14.0% [28/200]), etoricoxib (5.5% [11/200]), celecoxib 
(4.0% [8/200]), naproxen (3.0% [6/200]), and metamizole 
(2.0% [4/200]); the most frequently used concomitant co-
analgesics (used by $2% of patients) were pregabalin (3.0% 
[6/200]) and lidocaine (2.0% [4/200]).
Overall, 28.0% (56/200) of patients in the safety popula-
tion discontinued the study early. The reasons for study dis-
continuation included the following: AEs (12.0% [24/200]), 
withdrawal of consent for any reason (6.5% [13/200]), lack 
of efficacy (3.5% [7/200]), noncompliance (0.5% [1/200]), 
or other reasons (5.5% [11/200]).
In the main analysis population, the mean (SD) total daily 
dose of tapentadol prolonged release that patients were tak-
ing at Week 6 was 256.9 (111.38) mg. The mean (SD) total 
daily dose of tapentadol immediate release that patients in 
the main analysis population were taking at Week 6 was 6.7 
(21.16) mg. The majority of patients (88.8% [142/160]) had 
not taken any tapentadol immediate release during the 3 days 
prior to the Week 6 visit.
Effectiveness, function, and quality of life
For the primary endpoint, the mean (SD) pain intensity score 
(LOCF) decreased from 7.5 (1.08) at baseline to 4.1 (2.11) 
at Week 6; the mean (SD) change in pain intensity (LOCF) 
from baseline to Week 6 was −3.4 (2.10; P , 0.0001). 
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Figure 1 History of osteoarthritis knee pain (safety population).
Notes: aSD, 7.42 years; bSD, 28.17 months; cSD, 14.04 times; dSD, 1.32 doctors; eSD, 1.45 consultations; fSD, 1.10 consultations; gSD, 2.53 regimens.
Abbreviation: SD, standard deviation.
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Mean pain intensity over time is shown in Figure 2 for the 
overall population and opioid-naïve and opioid-experienced 
patients. In the overall population, mean pain intensity 
scores improved significantly from baseline to Week 6 (mean 
[SD] change from baseline, −3.8 [1.94]; P , 0.0001), from 
baseline to Week 8 (−4.2 [2.01]; P , 0.0001), and from 
baseline to Week 12 (−4.4 [1.91]; P , 0.0001). Significant 
improvements from baseline in mean pain intensity scores 
were observed at Weeks 6, 8, and 12, regardless of prior 
opioid experience (Figure 2). For opioid-naïve patients, the 
mean (SD) change in pain intensity from baseline to Week 
6 was −3.8 (1.90; P , 0.0001), from baseline to Week 8 
was −4.1 (1.92; P , 0.0001), and from baseline to Week 12 
was −4.3 (1.76; P , 0.0001). For opioid-  experienced patients, 
the mean (SD) change in pain intensity from   baseline to 
Week 6 was −3.9 (2.08; P , 0.0001), from baseline to Week 
8 was −4.4 (2.23; P , 0.0001), and from baseline to Week 
12 was −4.6 (2.21; P , 0.0001).
Responder rate 1 (the percentage of patients with a 
decrease in average pain intensity [11-point NRS-3] from 
baseline of $1 point) was 96.9% (155/160) at Week 6 and 
was significantly different from the null hypothesis responder 
rate 1 of 50% (P , 0.0001). Responder rate 2 (the percentage 
of patients with a decrease in average pain intensity [11-point 
NRS-3] from baseline of $1 point and an improvement 
in patient-rated satisfaction with treatment [5-point VRS] 
of $1 category) was 88.8% (142/160) at Week 6 and was 
significantly different from the null hypothesis responder 
rate 2 of 50% (P , 0.0001). When the LOCF was used for 
imputing missing assessments, responder rate 1 was 91.8% 
(179/195) and responder rate 2 was 78.5% (153/195) at 
Week 6 (P , 0.0001 versus the null hypothesis responder 
rate [50%] for responder rates 1 and 2).
At baseline (under prior WHO Step I or II treatment or 
no regular analgesic treatment), 2.1% (4/195) of patients 
reported “excellent”, “very good”, or “good” satisfac-
tion with treatment; the percentage of patients reporting 
these satisfaction ratings increased to 89.4% (143/160) at 
Week 6 and 92.0% (115/125) at Week 12 (Figure 3). Results 
of PGIC assessments at Weeks 1, 6, and 12 are summarized in 
Table 1 WHO Step II analgesics used during Week −1 (safety 
population)
WHO Step II analgesic, n (%) Total 
(n = 200)
Tramadol 17 (8.5)
Codeine, paracetamol 15 (7.5)
Paracetamol, tramadol 13 (6.5)
Tilidine, naloxone 5 (2.5)
Dextropropoxyphene, paracetamol 5 (2.5)
Caffeine, papaver somniferum latex, paracetamol 2 (1.0)
Other analgesics and antipyretics 2 (1.0)
Abbreviation: WHO, World Health Organization.
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Figure 2 Mean pain intensity (nRS-3) over time for the overall population and opioid-naïve and opioid-experienced patients (main analysis population; observed-case analysis).a
Notes: aData from Weeks 9 through 12 for patients in the Substudy A population were excluded; bSDs: BL, 1.08; W1, 1.70; W2, 1.85; W3, 1.85; W4, 1.84; W5, 1.92; W6, 
1.82; W7, 1.83; W8, 1.79; W9, 1.83; W10, 1.76; W11, 1.73; W12, 1.74; cSDs: BL, 1.09; W1, 1.66; W2, 1.76; W3, 1.75; W4, 1.68; W5, 1.75; W6, 1.69; W7, 1.71; W8, 1.67; 
W9, 1.53; W10, 1.54; W11, 1.47; W12, 1.56; dSDs: BL, 1.06; W1, 1.83; W2, 2.11; W3, 2.11; W4, 2.21; W5, 2.27; W6, 2.14; W7, 2.15; W8, 2.07; W9, 2.37; W10, 2.20; W11, 
2.24; W12, 2.10; eP , 0.0001 for the change from BL for the total population, opioid-naïve patients, and opioid-experienced patients.
Abbreviations: nRS-3, numerical rating scale-3; BL, baseline; SD, standard deviation; W, Week.
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  Figure 4. On the PGIC, a rating of “very much improved” or 
“much improved” was reported by 9.4% (18/191) of patients 
at Week 1, 55.6% (89/160) of patients at Week 6, and 69.6% 
(87/125) of patients at Week 12. Similar improvements were 
observed in CGIC ratings over time; a rating of “very much 
improved” or “much improved” was reported by 12.0% 
(23/191) of investigators at Week 1, 63.8% (102/160) of 
investigators at Week 6, and 76.8% (96/125) of investigators 
at Week 12.
The WOMAC osteoarthritis index pain, stiffness, and 
physical function subscale scores and the WOMAC global 
score all improved significantly from baseline to Weeks 
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Figure 3 Patient satisfaction with treatment (main analysis population; observed-case analysis).a
Note: aData from Weeks 9 through 12 for patients in the Substudy A population were excluded.
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Figure 4 PGIC ratings at Weeks 1, 6, and 12 (main analysis population; observed-case analysis).a
Note: aData from Weeks 9 through 12 for patients in the Substudy A population were excluded.
Abbreviation: PGIC, patient global impression of change.
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6, 8, and 12 (P , 0.0001 for all comparisons; Figure 5). 
Mean (SD) WOMAC scores at baseline and mean (SD) 
changes from baseline to Weeks 6, 8, and 12 are summarized 
in Table 2.
Significant improvements from baseline in the mean 
EQ-5D health status index score were observed at Weeks 6, 
8, and 12. The mean (SD) EQ-5D health status index score 
was 0.42 (0.300) at baseline and increased to 0.66 (0.203) 
by Week 6, 0.67 (0.223) by Week 8, and 0.69 (0.247) by 
Week 12. The mean (SD) change from baseline in the EQ-5D 
health status index score was 0.23 (0.304) at Week 6, 0.24 
(0.323) at Week 8, and 0.27 (0.339) at Week 12 (P , 0.0001 
for all comparisons).
Mean SF-36 physical and mental component summary 
scores improved significantly from baseline to Weeks 6 and 
12 (P , 0.005 for all comparisons; Table 3). Significant 
improvements from baseline were also observed in all mean 
SF-36 individual domain scores at Week 6 (P , 0.001 for 
all comparisons; Figure 6A) and at Week 12 (P , 0.05 for 
all comparisons; Figure 6B).
Although baseline mean HADS anxiety and depres-
sion subscale scores were 7 or less (ie, in the range below 
the occurrence of signs of clinically manifested anxiety or 
depression), significant improvements were observed from 
baseline to Weeks 6, 8, and 12 (P , 0.0001 for all compari-
sons; Appendix Table A7). The mean (SD) HADS anxiety 
subscale score at baseline was 6.7 (4.14), and the mean (SD) 
change from baseline was −1.5 (3.29) at Week 6 and −2.2 
(3.56) at Week 12. The mean (SD) HADS depression sub-
scale score at baseline was 7.0 (3.73), and the mean (SD) 
change from baseline was −1.3 (2.95) at Week 6 and −1.9 
(3.36) at Week 12.
Similar results were shown for pain intensity scores, 
patient satisfaction with treatment ratings, PGIC ratings, 
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Figure 5 Mean WOMAC osteoarthritis index subscale and global scores over time (main analysis population; observed-case analysis).a
Notes: aData from Weeks 9 through 12 for patients in the Substudy A population were excluded; bSDs: BL, 14.58; W6, 18.80; W8, 17.89; W12, 18.71; cSDs: BL, 11.06; W6, 
13.84; W8, 13.03; W12, 13.64; dSDs: BL, 3.11; W6, 3.93; W8, 3.72; W12, 3.86; eSDs: BL, 1.63; W6, 1.74; W8, 1.68; W12, 1.71; fP , 0.0001 for the change from BL.
Abbreviations: WOMAC, Western Ontario and McMaster Universities; SD, standard deviation; BL, baseline; W, Week.
Table 2 Mean (SD) baseline and changes from baseline in WOMAC scores (main analysis population; observed-case analysis)
WOMAC score Mean (SD) 
baseline score 
(n = 195)
Mean (SD) change from baseline
Week 6 
(n = 159)
Week 8 
(n = 153)
Week 12 
(n = 125)
Global scorea 53.6 (14.58) −21.0 (18.82)b −23.7 (18.35)b −27.6 (19.52)b
Pain subscalec 11.0 (3.11) −4.7 (4.38)b −5.2 (4.33)b −6.2 (4.45)b
Stiffness subscaled 4.4 (1.63) −1.8 (2.03)b −2.1 (1.99)b −2.5 (2.05)b
Physical function subscalee 38.2 (11.06) −14.5 (13.40)b −16.3 (12.94)b −18.9 (14.10)b
Notes: aPossible score, 0 to 96; bP , 0.0001 for the change from baseline; cPossible score, 0 to 20; dPossible score, 0 to 8; ePossible score, 0 to 68.
Abbreviations: SD, standard deviation; WOMAC, Western Ontario and McMaster Universities.
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Table 3 Mean (SD) baseline and changes from baseline in SF-36 summary scores (main analysis population; observed-case analysis)
SF-36 summary score Mean (SD)  
baseline score 
(n = 195)
Mean (SD) change from baseline
Week 6 
(n = 159)
Week 8 
(n = 153)
Week 12 
(n = 125)
Physical component 28.1 (8.51) 7.7 (10.20)a 8.7 (9.97)a 10.7 (11.02)a
Mental component 50.7 (11.46) 2.7 (10.27)a 2.0 (10.05)a 3.3 (11.05)a
Note: aP , 0.05 for the change from baseline.
Abbreviations: SD, standard deviation; SF-36, Short Form-36.
CGIC ratings, WOMAC scores, the EQ-5D health status 
index score, SF-36 scores, and HADS anxiety and depression 
subscale scores, regardless of whether results from Weeks 9 
through 12 for patients who participated in Substudy A were 
included or excluded (Appendix Tables A1–A7). Consistent 
improvements in those measures were also shown whether 
LOCF was used for imputing missing data or no imputation 
method was used (observed-case analysis; Appendix 
Tables A1–A7).
Substudy A
The majority (81.0% [17/21]) of patients who enrolled in 
Substudy A reduced their dose of concomitant WHO Step I 
analgesics or co-analgesics by 100% from Week 9 to Week 11; 
an additional 9.5% (2/21) of patients reduced their dose by 50% 
and 9.5% (2/21) of patients reduced their dose by 0%. Twenty of 
the 21 patients in Substudy A tapered a WHO Step I analgesic 
(ibuprofen; paracetamol; indometacin; diclofenac, misopros-
tol; diclofenac; etoricoxib; metamizole; or naproxen), and the 
remaining patient tapered a co-analgesic (duloxetine). Of the 
patients tapering WHO Step I analgesics, 80.0% (16/20) tapered 
their dose by 100% and 10.0% (2/20) tapered their dose by 50%; 
the remaining 2 patients (who were both taking paracetamol) 
did not taper their dose (0% reduction). For the patient who was 
tapering duloxetine, the dose was tapered by 100%.
For patients in Substudy A, mean (SD) pain intensity 
decreased significantly from baseline (8.0 [1.02]) to Week 6 
(4.2 [0.98]; P , 0.0001 for the change from baseline); further 
significant reductions from baseline were observed prior to 
tapering at Week 8 (4.0 [1.20]; P , 0.0001 for the change 
from baseline) and after tapering at Week 12 (3.7 [1.63]; 
P , 0.0001 for the change from baseline). Responder rate 
1 in Substudy A was 100% (21/21) at Week 6, and remained 
relatively stable at Week 8 (100% [21/21]) and Week 12 
(94.7% [18/19]; P , 0.0001 versus the null hypothesis 
responder rate [50%] at Weeks 6, 8, and 12). Similar results 
were observed over the course of the study for responder rate 
2 in Substudy A (Week 6, 95.2% [20/21]; Week 8, 100.0% 
[21/21]; Week 12, 89.5% [17/19]; P # 0.0006 versus the null 
hypothesis responder rate [50%] at Weeks 6, 8, and 12).
Tolerability
No clinically relevant changes from baseline to the end of 
study treatment were observed in any of the standard safety 
parameters, including vital sign measures, laboratory values, 
or physical examination findings.
Overall, 98.0% (196/200) of patients in the safety 
population reported non–treatment-emergent AEs; the 
majority of these AEs were associated with ongoing medical 
problems.
In the safety population, 71.0% (142/200) of patients 
reported a TEAE. The most common TEAEs are summa-
rized in Table 4. A total of 57.8% (243/421) of TEAEs were 
considered to be at least possibly related to study medication 
(Table 5). The majority of TEAEs (95.7% [288/301]) were 
considered to be of mild or moderate intensity.
Serious TEAEs were reported for 4.0% (8/200) of 
patients. Serious TEAEs included unstable angina, myocar-
dial infarction, cellulitis, respiratory tract infection, urinary 
tract infection, radius fracture, back pain, facial palsy, panic 
attack, and deep vein thrombosis; no individual serious AE 
was reported for more than 1 patient. TEAEs leading to 
premature study discontinuation were reported for 12.5% 
(25/200) of patients. The reason for one of these AE-related 
study discontinuations, which occurred due to the serious 
AEs of urinary tract infection and back pain that were not 
caused by the study medication, was listed among “other 
reasons” by the investigator. The most common TEAEs 
leading to study discontinuation (incidence $2%) included 
nausea (2.5% [5/200]) and dry mouth (2.0% [4/200]).
Discussion
Results of this open-label, phase 3b study suggest 
that tapentadol prolonged release (50–250 mg bid), in 
combination with tapentadol immediate release for acute 
pain episodes due to index pain, is effective and well tolerated 
for managing severe, chronic osteoarthritis-related knee 
pain that is inadequately managed with WHO Step I or II 
opioid analgesics, co-analgesics, or with no regular analgesic 
treatment. The low overall discontinuation rate and the low 
discontinuation rate due to AEs was likely related to the use 
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of lower average daily doses of tapentadol prolonged release, 
which may have resulted from the concomitant use of WHO 
Step I analgesics or co-analgesics and the 2 complementary 
mechanisms of action of tapentadol. The concomitant use 
of WHO Step I analgesics or co-analgesics with tapentadol 
prolonged release may be common for chronic pain patients 
in clinical practice; thus, results of this study indicate that 
tapentadol prolonged release treatment may be associated 
with good patient adherence to treatment in a clinical setting. 
Mean pain intensity decreased significantly over the course 
of the study, regardless of imputation method or prior opioid 
experience. The use of tapentadol prolonged release alone 
and in combination with tapentadol immediate release was 
associated with significant pain relief; however, the majority 
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Figure 6 Mean changes in SF-36 domain scores from baseline to (A) Week 6 and (B) Week 12 (main analysis population; observed-case analysis).
Notes: aSD: physical functioning, 23.42; role-physical, 46.29; bodily pain, 23.46; general health, 14.72; vitality, 20.44; social functioning, 26.75; role-emotional, 42.29; mental 
health, 17.80; bP , 0.05 for the change from baseline; cSD: physical functioning, 26.04; role-physical, 46.45; bodily pain, 25.04; general health, 17.65; vitality, 20.92; social 
functioning, 25.81; role-emotional, 46.91; mental health, 19.58; dData from Weeks 9 through 12 for patients in the Substudy A population were excluded.
Abbreviations: SF-36, Short Form-36; SD, standard deviation.
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Table 4 Incidences of TEAEs reported by $5% of patients (safety 
population)
System organ class, n (%) 
TEAE, n (%)
Total 
(n = 200)a
Any TEAE 142 (71.0)
Gastrointestinal disorders 77 (38.5)
  nausea 26 (13.0)
  Constipation 21 (10.5)
  Dry mouth 20 (10.0)
  Diarrhea 11 (5.5)
  Vomiting 10 (5.0)
nervous system disorders 55 (27.5)
  Dizziness 24 (12.0)
  Somnolence 14 (7.0)
  Headache 13 (6.5)
General disorders and administration site conditions 35 (17.5)
  Fatigue 21 (10.5)
Infections and infestations 34 (17.0)
  nasopharyngitis 16 (8.0)
Note: aIndicates the number of patients in the safety population, not the number 
of TEAEs.
Abbreviation: TEAE, treatment-emergent adverse event.
Table 5 Relationship of the most commonly reported (incidence $5%) TEAEs to tapentadol treatment (safety population)a
System organ class, n (%) 
TEAE, n (%)
No. of  
events
Not 
related
Unlikely  
related
Possibly  
related
Probably or  
likely related
Certainly  
related
Missing
Any TEAE 421 143 (34.0) 34 (8.1) 174 (41.3) 57 (13.5) 12 (2.9) 1 (0.2)
Gastrointestinal disorders 115 14 (12.2) 4 (3.5) 65 (56.5) 26 (22.6) 6 (5.2) 0
  nausea 29 1 (3.4) 0 18 (62.1) 8 (27.6) 2 (6.9) 0
  Constipation 22 0 0 9 (40.9) 11 (50.0) 2 (9.1) 0
  Dry mouth 20 2 (10.0) 0 14 (70.0) 3 (15.0) 1 (5.0) 0
  Diarrhea 11 2 (18.2) 2 (18.2) 7 (63.6) 0 0 0
  Vomiting 10 2 (20.0) 2 (20.0) 3 (30.0) 2 (20.0) 1 (10.0) 0
nervous system disorders 68 11 (16.2) 2 (2.9) 37 (54.4) 17 (25.0) 1 (1.5) 0
  Dizziness 25 1 (4.0) 0 15 (60.0) 8 (32.0) 1 (4.0) 0
  Somnolence 14 0 0 10 (71.4) 4 (28.6) 0 0
  Headache 13 3 (23.1) 1 (7.7) 5 (38.5) 4 (30.8) 0 0
General disorders and  
administration site conditions
38 9 (23.7) 3 (7.9) 19 (50.0) 5 (13.2) 2 (5.3) 0
  Fatigue 22 2 (9.1) 1 (4.5) 16 (72.7) 2 (9.1) 1 (4.5) 0
Infections and infestations 48 43 (89.6) 4 (8.3) 1 (2.1) 0 0 0
  nasopharyngitis 21 20 (95.2) 1 (4.8) 0 0 0 0
Note: aThe relationship of TEAEs to tapentadol treatment was evaluated as described in the Appendix.
Abbreviation: TEAE, treatment-emergent adverse event.
of patients did not require tapentadol immediate release once 
they had achieved stable dosing with tapentadol prolonged 
release (by Week 6). The concomitant administration of 
tapentadol immediate release was not associated with any 
negative impact on overall tolerability in the current study. 
Both responder rate 1 (the percentage of patients with a 
decrease in average pain intensity [11-point NRS-3] of 
$1) and responder rate 2 (the percentage of patients with a 
decrease in average pain intensity of $1 and an improvement 
in patient-rated satisfaction with treatment [5-point VRS] 
of $1 category) were significantly higher than the null 
hypothesis responder rate of 50% at Week 6, regardless of 
imputation method. Taken together, the improvements in 
pain intensity and responder rates suggest that tapentadol 
prolonged release treatment is associated with significant 
improvements in pain relief relative to prior treatment 
regimens (WHO Step I or II analgesics or co-analgesics or 
no regular analgesic treatment), even in patients who rotate 
directly from WHO Step II analgesics. Similar improvements 
in pain intensity and responder rates were observed in patients 
who tapered WHO Step I analgesics or co-analgesics from 
Weeks 9 to 11 in Substudy A, suggesting that tapering these 
analgesics and co-analgesics has no relevant therapeutic 
impact on the effectiveness of tapentadol prolonged release. 
Tramadol was the most commonly used WHO Step II 
analgesic during Week −1; the significant improvements 
in mean pain intensity observed in the current study with 
tapentadol in patients who had failed to respond to treatment 
with tramadol may be indicative of the higher analgesic 
strength of tapentadol relative to tramadol.
Both observed-case analysis and LOCF were used to 
evaluate all major effectiveness, function, and quality-of-
life analyses in this study. Observed-case analysis was used 
for the main results presented throughout this manuscript 
because results using this method were thought to better 
represent data observed in clinical practice settings than 
results of analyses using LOCF. When no imputation method 
is used (observed-case analysis), data for those patients who 
discontinue prematurely are omitted; although observed-case 
analysis may introduce some bias (because discontinuations 
are typically associated with response to treatment and are 
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not random), the results may be a more accurate reflection 
of the true study data. In contrast, when LOCF is used for 
imputing missing data, the missing values are assumed to 
be the same as the last recorded value, which is unlikely 
for patients who discontinue. In this study, the results of 
analyses using LOCF imputation were consistent with those 
observed when no imputation method was used, supporting 
the validity of the results. No clinically relevant differences 
were observed for the major effectiveness, function, and 
quality-of-life measures, regardless of whether results from 
Weeks 9 through 12 for patients participating in Substudy 
A were included or excluded, indicating that tapering of 
WHO Step I analgesics or co-analgesics in Substudy A had 
no clinically relevant impact on these measures.
The current study may have been limited by the lack of a 
placebo or active comparator. However, study results were in 
line with those observed in a previous randomized, double-
blind, placebo- and active-controlled study that evaluated the 
efficacy and safety of 15 weeks (3-week titration period and 
12-week maintenance period) of tapentadol prolonged 
release (100–250 mg bid) treatment for moderate to severe, 
chronic osteoarthritis-related knee pain.24 Due to the specific 
selection criteria, the population in a clinical study may not 
be completely representative of the population observed 
in a general clinical practice setting, which could include 
patients with severe osteoarthritis knee pain who have 
multiple co-morbidities or advanced illnesses; these patients 
have to be excluded from a clinical trial because of ethical 
safety-related concerns based on precautions, warnings, and 
contraindications according to the Summaries of Product 
Characteristics for compounds used in the trial or to avoid 
confounding factors that could potentially bias trial results 
(eg, conditions other than the index pain under evaluation 
that are associated with pain or a major negative impact 
on quality-of-life or function parameters). For that reason, 
caution should be exercised in interpreting these results for 
the general population of patients with osteoarthritis pain.
There is a growing body of evidence that supports the 
role of disturbed descending pain inhibition in osteoarthritis 
pain.13,14,37,38 The prevalence of chronic pain following joint 
replacement surgery ranges from 27% to 44%39–41; central sen-
sitization associated with disturbed descending pain inhibition 
is thought to contribute to this pain following joint replace-
ment.42 Continuous mechanical stimulation resulting from 
degradation of the cartilage also contributes to osteoarthritis 
pain.43 The µ-opioid agonist activity of tapentadol may be 
more effective at controlling the nociceptive pain arising 
from cartilage degradation, while the noradrenaline reuptake 
inhibitor activity of tapentadol may be more effective for re-
establishing descending inhibitory pain pathways.
The significant improvements in pain intensity observed 
with tapentadol treatment were accompanied by significant 
improvements from baseline to Weeks 6 and 12 in the 
WOMAC pain, stiffness, physical function, and global 
scores, as well as in the SF-36 index and summary scores 
and the EQ-5D health status index score in patients with 
severe, chronic osteoarthritis-related knee pain. By Week 6, 
the mean change from baseline in the EQ-5D health status 
index score (0.23) exceeded the threshold for a minimally 
clinically important difference (0.074)44 and stayed above 
this threshold for the remainder of the study. Clinically 
meaningful improvements ($5 points)45 from baseline were 
also observed in mean scores for all 8 SF-36 individual 
domains and the physical component summary at Weeks 
6 and 12. Treatment with tapentadol was also associated 
with significant improvements from baseline in mean 
HADS anxiety and depression subscale scores at Weeks 6 
and 12. The improvements observed in HADS anxiety and 
depression subscale scores were of lesser clinical relevance 
because baseline HADS anxiety and depression subscale 
scores were 7 or less and did not indicate the presence of 
clinically manifested anxiety and depression, respectively. 
These improvements in measures of health status, quality 
of life, pain, stiffness, and physical function were matched 
by corresponding improvements in patients’ and clinicians’ 
global impressions of change in patients’ overall conditions 
and patient-rated satisfaction with treatment.
In a meta-analysis8 of 18 placebo-controlled studies of 
opioids for the management of osteoarthritis pain, opioid 
treatment was associated with significant improvements in 
pain intensity compared with placebo (pooled effect size 
versus placebo, −0.79 [95% confidence interval, −0.98 
to −0.59]) and small improvements in function, based on the 
WOMAC physical function subscale (−0.31 [−0.39 to −0.24]). 
However, patient compliance with treatment was limited by 
low tolerability, with approximately 25% of patients discon-
tinuing treatment because of AEs.8 Gastrointestinal TEAEs, 
specifically nausea, vomiting, and constipation, may be 
particularly problematic for patients taking long-term opioid 
treatment for chronic pain. In a survey of 316 patients with 
chronic pain who were being treated with opioid analgesics, 
gastrointestinal side effects were reported as being among the 
most bothersome side effects and medication preference was 
largely determined by avoiding the occurrence of nausea and 
vomiting.46 In a randomized, double-blind, placebo-controlled 
study47 of oxycodone controlled release (average total daily 
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dose, 44 mg) for the management of moderate to severe 
osteoarthritis pain, nausea, vomiting, and constipation were 
reported for 41.1%, 12.5%, and 48.2% of patients, respec-
tively, and 36% of patients withdrew from the study because 
of AEs. In contrast, nausea, vomiting, and constipation were 
reported by 13.0%, 5.0%, 10.5% of patients, respectively, in 
the current study and only 12.0% of patients withdrew from 
the study because of AEs.
Results of the current open-label phase 3b study sup-
port those of other previous randomized, placebo- and/
or active-controlled studies in patients with moderate to 
severe, chronic osteoarthritis pain,25,26 and suggest that tap-
entadol prolonged release (50–250 mg bid) with tapentadol 
immediate release on-demand is effective and well toler-
ated for the management of severe, chronic osteoarthritis-
related knee pain in patients with inadequately managed 
pain, including those rotating directly from WHO Step II 
analgesics.
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Appendix
Determining the relationship of AEs  
to tapentadol and the association  
of AEs with previously or concomitantly 
received WHO Step I or II analgesics  
or co-analgesics
An AE was considered to be not related to study treatment 
if there was sufficient evidence to accept that there was no 
causal relationship to study medication administration (ie, 
no temporal relationship to study medication administra-
tion or another cause was demonstrated for the AE) and was 
considered to be unlikely related to study treatment if there 
was insufficient evidence to accept that there was no causal 
relationship to study medication administration, but there was 
no evidence to suggest a causal relationship (eg, a temporal 
relationship to study medication administration that makes a 
causal relationship improbable, and other drugs, chemicals, 
or underlying disease provide plausible explanations). An AE 
was considered to be possibly related to the study medication 
if there was limited evidence suggesting a causal relation-
ship (eg, reasonable temporal relationship between study 
medication administration and the AE, but the AE could also 
be explained by concurrent disease or other drugs); probably 
or likely related to the study medication if there was sufficient 
evidence to suggest a causal relationship (eg, reasonable 
temporal relationship between study medication administra-
tion and the AE, and the AE was unlikely to be related to a 
concurrent disease or other drug); and certainly related to 
the study medication if there was clear evidence for a causal 
relationship (eg, reasonable temporal relationship between 
study medication administration and the AE, and the AE 
could not be explained by concurrent disease or other drugs). 
All AEs were also evaluated to determine an association with 
any of the previously or concomitantly received WHO Step 
I or II analgesics or co-analgesics; if any of the AEs could 
be at least possibly associated with any of the analgesics or 
co-analgesics, the causality was recorded.
Table A1 Mean (SD) pain intensity scores (11-point nRS-3) overall and by prior opioid experience at baseline and at Weeks 6 and 12 
using observed-case analysis (with and without the Week 9–12 data for the Substudy A population) and using the LOCF (without the 
Week 9–12 data for the Substudy A population) – main analysis population
Population Baseline Observed-case analysis LOCF
Week 6 Week 12 Week 6 Week 12
Without  
Substudy A
With  
Substudy A
Without  
Substudy A
Total (n = 195) (n = 160) (n = 125) (n = 144) (n = 193) (n = 172)
7.5 (1.08) 3.6 (1.82)a 2.9 (1.74)a 3.0 (1.74)a 4.1 (2.11)a 3.7 (2.28)a
Opioid naïve (n = 139) (n = 116) (n = 86) (n = 104) (n = 139) (n = 119)
7.5 (1.09) 3.7 (1.69)a 3.0 (1.56)a 3.1 (1.55)a 4.1 (1.99)a 3.7 (2.15)a
Opioid experienced (n = 56) (n = 44) (n = 39) (n = 40) (n = 54) (n = 53)
7.6 (1.06) 3.5 (2.14)a 2.8 (2.10)a 2.9 (2.17)a 4.1 (2.41)a 3.7 (2.57)a
Note: aP , 0.0001 for the change from baseline.
Abbreviations: SD, standard deviation; nRS-3, numerical rating scale-3; LOCF, last observation carried forward.
Table A2 Patient satisfaction with treatment ratings at baseline and at Weeks 6 and 12 using observed-case analysis (with and without 
the Week 9–12 data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the Substudy A population)   
– main analysis population
Satisfaction  
rating, n (%)
Baseline 
(n = 195)
Observed-case analysis LOCF
Week 6 
(n = 160)
Week 12 Week 6 
(n = 193)
Week 12
Without  
Substudy A 
(n = 125)
With  
Substudy A 
(n = 144)
Without  
Substudy A 
(n = 172)
Excellent 0 16 (10.0) 16 (12.8) 17 (11.8) 16 (8.3) 17 (9.9)
Very good 0 39 (24.4) 45 (36.0) 52 (36.1) 41 (21.2) 47 (27.3)
Good 4 (2.1) 88 (55.0) 54 (43.2) 63 (43.8) 95 (49.2) 69 (40.1)
Fair 126 (64.6) 17 (10.6) 9 (7.2) 11 (7.6) 29 (15.0) 26 (15.1)
Poor 64 (32.8) 0 1 (0.8) 1 (0.7) 12 (6.2) 13 (7.6)
Missing 1 (0.5) 0 0 0 0 0
Abbreviation: LOCF, last observation carried forward.
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Table A4 Mean (SD) WOMAC scores at baseline and at Weeks 6 and 12 using observed-case analysis (with and without the Week 
9–12 data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the Substudy A population) – main 
analysis population
WOMAC score Baseline 
(n = 195)
Observed-case analysis LOCF
Week 6 
(n = 159)
Week 12 Week 6 
(n = 185)
Week 12
Without  
Substudy A 
(n = 125)
With  
Substudy A 
(n = 144)
Without  
Substudy A 
(n = 164)
Global scorea 53.6 (14.58) 32.1 (18.80)b 26.7 (18.71)b 27.2 (18.58)b 34.2 (19.87)b 30.7 (20.71)b
Pain subscalec 11.0 (3.11) 6.3 (3.93)b 5.1 (3.86)b 5.2 (3.83)b 6.7 (4.25)b 5.9 (4.40)b
Stiffness subscaled 4.4 (1.63) 2.5 (1.74)b 2.0 (1.71)b 2.0 (1.73)b 2.7 (1.82)b 2.3 (1.89)b
Physical function subscalee 38.2 (11.06) 23.3 (13.84)b 19.7 (13.64)b 20.1 (13.55)b 24.8 (14.48)b 22.4 (14.96)b
Notes: aPossible score, 0 to 96; bP , 0.0001 for the change from baseline; cPossible score, 0 to 20; dPossible score, 0 to 8; ePossible score, 0 to 68.
Abbreviations: SD, standard deviation; WOMAC, Western Ontario and McMaster Universities; LOCF, last observation carried forward.
Table A5 Mean (SD) EQ-5D health status index score at baseline and at Weeks 6 and 12 using observed-case analysis (with and 
without the Week 9–12 data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the Substudy A 
population) – main analysis population
Baseline 
(n = 195)
Observed-case analysis LOCF
Week 6 
(n = 159)
Week 12 Week 6 
(n = 185)
Week 12
Without  
Substudy A 
(n = 125)
With  
Substudy A 
(n = 144)
Without 
Substudy A 
(n = 164)
EQ-5D health  
status index score
0.4 (0.30) 0.7 (0.20)a 0.7 (0.25)a 0.7 (0.23)a 0.6 (0.23)a 0.6 (0.28)a
Note: aP , 0.0001 for the change from baseline.
Abbreviations: SD, standard deviation; EQ-5D, EuroQol-5 Dimension; LOCF, last observation carried forward.
Table A3 PGIC and CGIC ratings at baseline and at Weeks 6 and 12 using observed-case analysis (with and without the Week 9–12 
data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the Substudy A population) – main analysis 
population
Rating, n (%) Observed-case analysis LOCF
Week 6 
(n = 160)
Week 12 Week 6 
(n = 193)
Week 12
Without  
Substudy A 
(n = 125)
With  
Substudy A 
(n = 144)
Without  
Substudy A 
(n = 172)
PGIC
  Very much improved 14 (8.8) 23 (18.4) 24 (16.7) 14 (7.3) 24 (14.0)
  Much improved 75 (46.9) 64 (51.2) 79 (54.9) 79 (40.9) 71 (41.3)
  Minimally improved 58 (36.3) 33 (26.4) 35 (24.3) 67 (34.7) 48 (27.9)
  no change 8 (5.0) 5 (4.0) 6 (4.2) 18 (9.3) 17 (9.9)
  Minimally worse 2 (1.3) 0 0 7 (3.6) 5 (2.9)
  Much worse 2 (1.3) 0 0 5 (2.6) 4 (2.3)
  Very much worse 0 0 0 3 (1.6) 3 (1.7)
  Missing 1 (0.6) 0 0 – –
CGIC
  Very much improved 14 (8.8) 28 (22.4) 29 (20.1) 14 (7.3) 29 (16.9)
  Much improved 88 (55.0) 68 (54.4) 83 (57.6) 93 (48.2) 79 (45.9)
  Minimally improved 47 (29.4) 27 (21.6) 28 (19.4) 56 (29.0) 41 (23.8)
  no change 7 (4.4) 2 (1.6) 4 (2.8) 15 (7.8) 12 (7.0)
  Minimally worse 2 (1.3) 0 0 10 (5.2) 8 (4.7)
  Much worse 1 (0.6) 0 0 3 (1.6) 2 (1.2)
  Very much worse 1 (0.6) 0 0 2 (1.0) 1 (0.6)
  Missing 0 0 0 – –
Abbreviations: PGIC, patient global impression of change; CGIC, clinician global impression of change; LOCF, last observation carried forward.
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Table A6 Mean (SD) SF-36 scores at baseline and at Weeks 6 and 12 using observed-case analysis (with and without the Week 9–12 
data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the Substudy A population) – main analysis 
population
Subscale or  
summary
Baseline 
(n = 195)
Observed-case analysis LOCF
Week 6 
(n = 159)
Week 12 Week 6 
(n = 185)
Week 12
Without  
Substudy A 
(n = 125)
With  
Substudy A 
(n = 144)
Without 
Substudy A 
(n = 164)
Role-physical 33.5 (41.70) 54.2 (43.59)a 65.0 (41.88)a 61.8 (42.63)a 53.1 (43.70)a 57.9 (43.85)a
Physical functioningb 30.4 (19.36) 47.6 (23.52)a 53.3 (25.56)a 52.7 (25.47)a 45.4 (24.78)a 48.5 (26.99)a
Bodily pain 32.5 (16.87) 54.0 (20.44)a 62.4 (21.97)a 61.0 (21.23)a 51.7 (21.59)a 56.4 (24.43)a
General healtha 46.3 (16.55) 55.8 (18.77)a 60.3 (20.04)a 58.6 (19.78)a 53.9 (19.01)a 55.9 (20.97)a
Vitality 46.8 (17.39) 56.1 (19.70)a 60.0 (21.85)a 58.5 (21.92)a 55.1 (19.27)a 56.9 (21.32)a
Social functioning 66.1 (25.63) 76.5 (23.88)a 82.7 (21.58)a 81.9 (21.97)a 75.5 (25.08)a 78.3 (26.08)a
Role-emotional 69.2 (41.44) 82.2 (35.73)a 81.1 (36.01)a 81.9 (35.01)a 80.7 (36.54)a 78.5 (37.61)a
Mental health 63.1 (19.95) 72.1 (17.70)a 75.0 (20.20)a 73.8 (20.35)a 70.5 (18.14)a 72.0 (20.51)a
Physical component 28.1 (8.51) 35.7 (10.20)a 39.3 (10.58)a 38.5 (10.56)a 34.9 (10.35)a 36.9 (11.24)a
Mental component 50.7 (11.46) 53.7 (10.13)a 54.1 (10.45)a 53.9 (10.56)a 53.2 (10.31)a 53.1 (11.02)a
Notes: aP , 0.05 for the change from baseline; bbaseline, n = 194; Observed-case analysis: Week 6, n = 159; Week 12, without Substudy A, n = 125; Week 12, with 
Substudy A, n = 144; LOCF: Week 6, n = 184; Week 12, n = 163.
Abbreviations: SD, standard deviation; SF-36, Short Form-36; LOCF, last observation carried forward.
Table A7 Mean (SD) HADS Anxiety and Depression Subscale scores at baseline and at Weeks 6 and 12 using observed-case analysis 
(with and without the Week 9–12 data for the Substudy A population) and using the LOCF (without the Week 9–12 data for the 
Substudy A population) – main analysis population
Subscale Baseline 
(n = 192)
Observed-case analysis LOCF
Week 6 
(n = 158)
Week 12 Week 6 
(n = 184)
Week 12
Without  
Substudy A 
(n = 124)
With  
Substudy A 
(n = 143)
Without 
Substudy A 
(n = 163)
Anxiety 6.7 (4.14) 5.2 (4.18)a 4.2 (4.26)a 4.4 (4.35)a 5.5 (4.17)a 5.0 (4.48)a
Depression 7.0 (3.73) 5.5 (3.86)a 4.9 (4.35)a 5.0 (4.23)a 5.8 (3.90)a 5.4 (4.29)a
Note: aP , 0.0001 for the change from baseline.
Abbreviations: SD, standard deviation; HADS, Hospital Anxiety and Depression Scale; LOCF, last observation carried forward.
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